# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Liliʻuokalani (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET024-SYN
- Date: 2026-08-24
- Fictional facility: St. Posthumous Health Center
- Fictional author: Kealani Morrison-Takeda, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Five-month review after the stroke. **S**

## History of present illness

Liliʻuokalani returns six weeks after her annual wellness visit, five months after the stroke. She has had no new neurological symptoms, no bleeding and no falls, and has finished arranging a new song. She takes apixaban twice daily without missed doses and does the balance exercises from the community program twice a week. Her home blood pressure averages 122/72. Her hepatitis C antibody test was negative, and her bone density scan showed osteopenia (lowest T-score -2.1 at the femoral neck) with a ten-year risk of hip fracture below the level at which medicine is advised. She would like her zoster and Tdap vaccines today. **S**

| Element | Detail |
|---|---|
| Events | No recurrence, bleeding or falls |
| Home blood pressure | Average 122/72 mmHg |
| Screening results | Hepatitis C negative; osteopenia, below the treatment threshold |
| Function | Composing and playing daily |
| Cognition | MoCA 27 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Neurological | Negative | No weakness, numbness, speech, vision or balance problem |
| Hematologic | Negative | No nosebleeds, bruising, black stools or blood in the urine |
| Musculoskeletal | Negative | No falls |

3 systems reviewed. **S**

## Current medications

- Atorvastatin 40 mg oral tablet, one tablet daily **S**
- Losartan 25 mg oral tablet, one tablet daily **S**
- Apixaban 5 mg oral tablet, one tablet twice daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/74 mmHg; pulse 70 bpm; respirations 16/min; temperature 36.5 °C; oxygen saturation 98% on room air; weight 57.8 kg; BMI 22.6 kg/m². All vital signs are synthetic.

Sodium: 139 mmol/L; Potassium: 4.3 mmol/L; Creatinine: 0.88 mg/dL; eGFR (CKD-EPI 2021): 67 mL/min/1.73 m²; Glucose: 94 mg/dL; Hemoglobin: 12.7 g/dL; Platelets: 226 10*3/uL; Total cholesterol: 134 mg/dL; LDL cholesterol: 62 mg/dL; HDL cholesterol: 57 mg/dL; Triglycerides: 90 mg/dL; MoCA: 27. All results are synthetic.

## Change since baseline

- Sodium: 139 mmol/L at baseline, 139 mmol/L at this visit **S**
- Potassium: 4.2 mmol/L at baseline, 4.3 mmol/L at this visit **S**
- Creatinine: 0.82 mg/dL at baseline, 0.88 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 73 mL/min/1.73 m² at baseline, 67 mL/min/1.73 m² at this visit **S**
- Glucose: 98 mg/dL at baseline, 94 mg/dL at this visit **S**
- Hemoglobin: 12.8 g/dL at baseline, 12.7 g/dL at this visit **S**
- Platelets: 232 10*3/uL at baseline, 226 10*3/uL at this visit **S**
- Total cholesterol: 214 mg/dL (high) at baseline, 134 mg/dL at this visit **S**
- LDL cholesterol: 132 mg/dL (high) at baseline, 62 mg/dL at this visit **S**
- HDL cholesterol: 58 mg/dL at baseline, 57 mg/dL at this visit **S**
- Triglycerides: 120 mg/dL at baseline, 90 mg/dL at this visit **S**

## Immunizations given today

- Recombinant zoster vaccine, dose 1 of 2 **S**
- Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 124/74, pulse 70 and regular; weight 57.8 kg |
| Cardiovascular | Regular rhythm; no murmur |
| Neurological | Normal speech, strength, fine finger movements and gait |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Minor ischemic stroke** (I63.412). No recurrence in five months; MoCA 27; LDL 62 mg/dL. **S**
   - Continue atorvastatin 40 mg; lipid panel yearly now that LDL is stable at goal.
2. **Paroxysmal atrial fibrillation on apixaban** (I48.0). Hemoglobin 12.7 g/dL, platelets 226 and creatinine 0.88 mg/dL (creatinine clearance about 48 mL/min): apixaban 5 mg twice daily remains the right dose. CHA2DS2-VASc and HAS-BLED to be reviewed yearly. **S**
   - Continue apixaban 5 mg twice daily.
   - Blood count and kidney function again in about five months, or sooner with any illness.
3. **Hypertension** (I10). At goal: 124/74 in the clinic and 122/72 at home. **S**
   - Continue losartan 25 mg; potassium and creatinine with the next blood tests.
4. **Osteopenia on bone density scan**. Below the threshold for medicine; falls matter more on an anticoagulant. **S**
   - Calcium-rich foods, vitamin D, walking and the balance program; repeat scan in two to three years.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure in the clinic and at home (target below 130/80 mmHg) and weight | Every visit | Completed today | 124/74 mmHg; home average 122/72; 57.8 kg |
| Laboratory | Potassium and creatinine after starting an angiotensin receptor blocker | About two weeks after starting, then every six months | Completed today | Potassium 4.3 mmol/L, creatinine 0.88 mg/dL (eGFR 67) |
| Medication safety | Antithrombotic therapy and adherence | Every visit | Completed today | Apixaban twice daily, no missed doses; no bleeding |
| Laboratory | Anticoagulant safety: blood count, kidney function (creatinine clearance) and liver tests | Before starting, then about every creatinine clearance / 10 months at age 75 or older (about every five months for her) | Completed today | Hemoglobin 12.7 g/dL, platelets 226; creatinine clearance about 48 mL/min; dose unchanged |
| Laboratory | Lipid panel (LDL goal below 70 mg/dL) | Four to twelve weeks after starting a statin, then every three to twelve months | Completed today | LDL 62 mg/dL, total cholesterol 134, HDL 57, triglycerides 90 |
| Survey | Cognitive screen (MoCA) | After the event, again within the first year, then periodically | Completed today | MoCA 27 within the first year after the stroke |
| Survey | Depression screen (PHQ-2, PHQ-9) | At the first post-stroke visit, then at least yearly | Up to date | PHQ-9 4 at three months; PHQ-2 0 at the wellness visit |
| Examination | Neurological status (NIH Stroke Scale at the event; modified Rankin Scale at 90 days) and new symptoms | With any change | Completed today | No new symptoms; examination normal |
| Imaging | ECG and prolonged rhythm monitoring for atrial fibrillation | ECG at baseline; at least 30 days of monitoring within six months of the event | Not indicated | Atrial fibrillation found and treated; no further monitoring needed |
| Examination | Falls risk | Every visit | Completed today | No falls; balance program twice a week |
| Self-management | Tobacco, alcohol and physical activity | Every visit | Completed today | Never smoker; alcohol rarely; walks daily |
| Self-management | Influenza vaccine | Yearly | Due | This season's high-dose vaccine in the autumn |
| Self-management | BE FAST and calling 911 | Every visit | Completed today | Reviewed |
| Self-management | Culturally safe care: her choices, ʻohana involvement and Native Hawaiian healing alongside clinic care | Every visit | Completed today | Her care continues as she directs, with her ʻohana and her own practices |

## Goal progress

- No recurrent stroke or transient ischemic attack. Outcome by 2026-08-24: None in five months on dual antiplatelets, then apixaban. **S**
- LDL cholesterol below 70 mg/dL. Outcome by 2026-04-20: 132 to 64 mg/dL on atorvastatin 40 mg. **S**
- Blood pressure below 130/80 mmHg at home and in the clinic. Outcome by 2026-06-15: 126/74 in the clinic; home average 124/72. **S**
- Anticoagulation that is safe and taken as prescribed, without major bleeding. Outcome by 2026-08-24: Apixaban 5 mg twice daily from five weeks; one minor nosebleed, controlled at home and in the clinic; no missed doses. **S**
- Keep playing the piano and composing. Outcome by 2026-06-15: Playing daily; modified Rankin Scale 1 at three months. **S**

## Guideline basis

- 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association (2021), American Heart Association and American Stroke Association (Stroke 2021;52(7):e364-e467)
- Primary Care of Adult Patients After Stroke: A Scientific Statement From the American Heart Association/American Stroke Association (2021), American Heart Association and American Stroke Association (Stroke 2021;52(9):e558-e571)
- 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023), American College of Cardiology, American Heart Association, American College of Chest Physicians and Heart Rhythm Society (Circulation 2024;149(1):e1-e156)
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)
- CMID: Clinical Monitoring Intelligence Database, stroke and transient ischemic attack, atrial fibrillation and hypertension monographs (2026), Aether Forge
- Signs and Symptoms of Stroke (2026), Centers for Disease Control and Prevention
- Ke Ola Mamo: a Native Hawaiian Health Care System serving Oʻahu (medical care, lomilomi and community health workers) (2026), Ke Ola Mamo
- Osteoporosis to Prevent Fractures: Screening (2025), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Zoster dose 1 and Tdap given today; second zoster dose in two to six months. Influenza and COVID-19 vaccines in the autumn. Review in three months. Call 911 for any BE FAST sign. **S**

